. 2018 Dec 18;42(5):587–601. doi: 10.1007/s40264-018-0760-1
© The Author(s) 2018
Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
Fig. 2.
Mitigation of key risks of blinatumomab treatment